Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

Fitoterapia is a prestigious journal published by Elsevier that specializes in the fields of drug discovery and pharmacology. Established in 1948 and featuring a comprehensive scope that encompasses all aspects of medicinal plants and their derivatives, this journal is a critical resource for researchers, professionals, and students interested in the pharmacological effects of natural products. With an impressive impact factor reflected in its Q2 ranking in both Drug Discovery and Medicine as well as a Q3 ranking in Pharmacology, Fitoterapia plays a vital role in promoting innovative research in the intersection of traditional medicine and modern pharmacological science. The journal’s commitment to quality is further highlighted by its rankings in Scopus, where it holds a notable position among peers in its field. Although Fitoterapia does not currently offer Open Access, its reputation for rigor and relevance makes it an indispensable asset for anyone engaged in herbal medicine research and development. Authors and researchers seeking to publish groundbreaking findings will find a welcoming platform to disseminate their work in this influential journal.

ALLERGOLOGIA ET IMMUNOPATHOLOGIA is a distinguished academic journal dedicated to the field of immunology and allergy, published by CODON PUBLICATIONS, based in Singapore. With its ISSN 0301-0546 and E-ISSN 1578-1267, this journal aims to provide an open platform for researchers and practitioners to share their findings, emphasizing topics related to immunopathology and respiratory health. Covering a broad scope from 1973 to 2024, it currently holds a notable position in several category quartiles, including Q3 in Immunology and Allergy, and Q3 in Pulmonary and Respiratory Medicine as of 2023. Despite the absence of an open access option, the journal maintains an essential role in disseminating pivotal research, reflected in its Scopus rankings that position it within the core of its discipline. With an impact factor acknowledging the significance of its contributions, ALLERGOLOGIA ET IMMUNOPATHOLOGIA continues to be a vital resource for ongoing education and advancement in immunological and allergic research.

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

Jundishapur Journal of Natural Pharmaceutical Products, published by BRIEFLAND in the Netherlands, serves as a pivotal platform for researchers and professionals in the realm of pharmacology and toxicology. With its ISSN 1735-7780 and E-ISSN 2228-7876, the journal has established itself since its inception in 2011, showcasing a commitment to advancing knowledge in natural pharmaceutical products through innovative research. In 2023, it earned a commendable ranking in the Q3 category for Pharmacology, Toxicology, and Pharmaceutics, reflecting its contribution to the field as evidenced by its position in the Scopus rankings. The journal aims to publish high-quality research articles, reviews, and case studies that explore the potential benefits and toxicological aspects of natural products. Although it currently does not offer open access, its rigorous peer-review process ensures that only impactful studies are disseminated, ultimately facilitating a deeper understanding of natural pharmaceutical innovations. For those engaged in this exciting and evolving field, Jundishapur Journal of Natural Pharmaceutical Products is an essential resource that not only expands scholarly discourse but also promotes safe practices in natural product utilization.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH is a prestigious publication in the field of natural products, focusing on valuable research spanning analytical chemistry, pharmacology, and complementary medicine. Published by Taylor & Francis Ltd in the United Kingdom, this journal has established itself as a key resource for academics and professionals seeking to explore advancements in drug discovery and organic chemistry. With a converged publication timeline from 1998 to 2024, the journal boasts several commendable category quartiles as of 2023, reflecting its robust standing in the research community: Q2 in Complementary and Alternative Medicine, Q3 in multiple domains including Analytical Chemistry and Organic Chemistry, and Q4 in Molecular Medicine. Although it currently does not offer open access, the journal remains a valuable compendium for empirical research and innovative studies in areas such as pharmacology and medicinal chemistry. Researchers, professionals, and students alike will find the JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH to be an essential platform for sharing groundbreaking findings and fostering collaborations that lead to significant advancements in science and health.